Dear reader,
This issue of Human Vaccines & Immunotherapeutics begins with three Novel Vaccines studies: Phase 1 safety and immunogenicity trials with Moderna’s mRNA-based RSV prefusion F protein vaccine (Aliprantis, p 1248) and with an adjuvanted Escherichia coli adhesin vaccine (Eldridge, p 1262), and a preclinical study of DENV-3 precursor membrane glycoprotein for enhanced protection from dengue (Dias, p 1271).
The Immunotherapy section presents a systematic review of metastatic sites as predictors of PD-1 blockade immunotherapy in non-small cell lung cancer (Huang, p 1278), an immune persistence study of the DNA immunotherapy VGX-3100 for the treatment of HPV-associated intraepithelial lesions (Bhuyan, p 1288), and a commentary on the immunotherapy of osteosarcoma (Yahiro, p 1294).
We introduce six articles on the novel Coronavirus, including a review of the epidemiology and genetics of coronaviruses and implications for the current pandemic and vaccination (Khan, p 1296), an online survey of Covid-19 literacy (Biasio, p 1304), an estimate of decline in childhood vaccinations due to the pandemic (Kitano, p 1313), and commentaries on prioritized populations for vaccination (Russell, p 1317), vaccine safety (Tau, p 1322), and hesitancy in US (Zizzo, p 1326).
The Licensed Vaccines segment features a literature review on subcutaneous administration (Cook, p 1329), sero-profiling of Italian health-care workers with respect to vaccine-preventable diseases (Coppeta, p 1342), cost analysis of a measles outbreak in China (Zhou, p 1347), assessment of measles antibody prevalence in Israel (Bassal, p 1349), long-term epidemiology of mumps in Shanghai (Pang, p 1358), safety and immunogenicity Phase 1 trial of a new Sabin inactivated poliovirus vaccine (Leroux-Roels, p 1366), a survey among veterinary students on Q fever vaccination (Rahaman, p 1374), and a case report on BCG disease following vaccination (Wang, p 1382).
Six Influenza-related articles present an impact analysis of lowered recommended age for free vaccination in Italy (Trucchi, p 1387), a review of gender differences in vaccine responses (Denly, p 1396), and surveys of barriers to vaccination in Shanghai (Yan, p 1403), and of knowledge and attitudes toward vaccination among Chinese adults (Jiang, p 1412), rheumatic disease patients (Figueroa-Parra, p 1420), and Saudi health-care professionals (Alharbi, p 1426).
The Meningococcal section presents a review of MenCV safety in the US (Becerra-Culqui, p 1432), analysis of antibody responses against hyper-virulent strains following prime-boost vaccination in children (Giuliani, p 1442), and a commentary on evaluating the effectiveness of the 4CMenB vaccine (Marshall, p 1450).
Three Pneumococcal articles investigate disease knowledge and vaccine uptake among Chinese elderly (Wang, p 1455), safety and immunogenicity of a 12-valent PCV in toddlers (Horn, p 1463), and invasive disease in Turkish children (Ustundag, p 1470).
The Public Health segment reports on the determinants of success of national vaccination programs for pregnant women (Privor-Dumm, p 1474), missed opportunities for vaccination in China (Chen, p 1483), and vaccine logistics management in Nigeria (Adebimpe, p 1490).
Three articles on Hepatitis include reviews on the long-term effects of HAV vaccination (Herzog, p 1496) and HAV vaccination in patients with chronic liver disease (Raju, p 1520), and a study of the impact of HBV vaccination on an entire isolated population (Liu, p 1530).
Finally, we present an assessment of RSV hospitalization rates in preterm infants following the discontinued Passive Immunization recommendation in the US (Fergie, p 1536) and an analysis of Rotavirus vaccine uptake patterns in Italy (Martinelli, p 1546).
Our monthly News, Policy and Profiles (NP&P) track offers a selection of the latest news in the field of vaccines and immunotherapeutics. In this section, we also regularly publish opinion pieces on timely, interesting, and controversial topics related to vaccines and immunotherapeutics, profiles of companies and organizations, as well as portraits of distinguished scientists in our field. Please contact Acquisitions Editor Adam Weiss ([email protected]) with your ideas for commentaries, opinion pieces, profiles, and portraits. Your suggestions for and contributions to our N&P&P track are always welcome!
Sincerely,
Ronald Ellis, PhD
Editor-in-Chief
Adam Weiss, PhD
Acquisitions Editor